US92942V2088 - Common Stock
VYANT BIO INC
NASDAQ:VYNT (5/12/2023, 7:07:00 PM)
After market: 0.2211 -0.04 (-14.96%)0.26
-0.08 (-23.51%)
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company is headquartered in Cherry Hill, New Jersey and currently employs 8 full-time employees. The company went IPO on 2013-04-10. The firm is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).
VYANT BIO INC
2 Executive Campus, 2370 State Route 70, Suite 310
Cherry Hill NEW JERSEY 07070
P: 12015289200.0
CEO: John A. Roberts
Employees: 8
Website: https://www.vyantbio.com/
CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders...
Biotech company Vyant Bio expects to make liquidation payments of $0.16 to $0.29 per share to its shareholders after being delisted from Nasdaq and selling...
Vyant Bio (VYNT) shareholders have approved a plan to dissolve the company, which sold substantially all of its assets in October. Read more here.
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of...
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of...
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of...
Here you can normally see the latest stock twits on VYNT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: